Generous Support From Seena Magowitz Foundation
FOR IMMEDIATE RELEASE
Media Contact: Miranda Landsman
New Personalized Clinical Trial For The Treatment of Pancreatic Cancer
Initiated By The Medical College of Wisconsin LaBahn Pancreatic Cancer Program
With Generous Support From The Seena Magowitz Foundation
PHOENIX, AZ October 2020 – Scientists have recently defined pancreatic cancer as having two distinct molecular subtypes (classical and basal-like); these subtypes may be predictive of response to chemotherapy. With generous support from the Seena Magowitz Foundation, the LaBahn Pancreatic Cancer Program at the Medical College of Wisconsin in Milwaukee has initiated a clinical trial which utilizes state-of-the-art molecular subtyping of endoscopic biopsy samples to guide treatment.
This multi-center trial will be conducted at the Medical College of Wisconsin, HonorHealth Research Institute in Scottsdale, Arizona, The Translational Genomics Research Institute in Phoenix and the University of North Carolina. The trial is expected to enroll 41 patients. Following molecular subtype determination, patients will receive a tailored chemotherapy program prior to surgery. (NCT03322995) for pancreatic cancer.
Read more about the clinical trial.
The LaBahn Pancreatic Cancer Program at the Medical College of Wisconsin in Milwaukee is an internationally renowned program comprised of a multidisciplinary team of physicians, scientists and dedicated staff who share a passion and urgency for making significant progress in the battle against pancreatic cancer. The program incorporates a robust volume of clinical trials for every stage of pancreatic cancer treatment and has led the way in innovative investigator initiated trials for patients with operable pancreatic cancer.
About The Medical College of Wisconsin LaBahn Pancreatic Cancer Program
Pancreatic cancer is a challenging disease with the lowest survival rate of any tumor-type cancer. Difficult to fight, but not impossible. Having the right team can make all the the difference. At MCW, its team of doctors and medical professionals have achieved international recognition for their work finding ways to diagnose and treat pancreatic cancer.
Dr. Douglas B. Evans, world renowned pancreatic cancer surgeon and research oncologist will be appearing along with Dr. Daniel Von Hoff, Dr. Talia Golan, and Dr. Erkut Borazanci at the December 4, 2020 Virtual Gala Celebration of Hope.
For more information, visit https://www.mcw.edu/departments/pancreatic-cancer.
About The Seena Magowitz Foundation
Known as “The Face and Voice of Pancreatic Cancer”, the Seena Magowitz Foundation works to provide the loudest voice of awareness of pancreatic cancer. The Foundation was founded by Roger. E. Magowitz in honor of his mother, Seena Magowitz, who lost her battle with pancreatic cancer in 2001. The Foundation is entering it 20th year of funding medical research in pursuit of innovative life-extending treatments of pancreatic cancer patients. Besides leading-edge treatments, it focuses on the discovery of easier methods of early detection with an ultimate mission of finding a cure. According to Roger Magowitz, “the foundation accepts the challenge”……”If Not Us, Then Who”